November 21, 2024

Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis – ACS Publications

November 20, 2024

Fig.3. Immunohistochemical evaluation of idiopathic pulmonary fibrosis… – ResearchGate

November 20, 2024

First Patient Dosed in Endeavor BioMedicines’ Phase 2b WHISTLE-PF Trial Evaluating ENV-101 for the Treatment of Idiopathic Pulmonary Fibrosis – Business Wire

November 18, 2024

New drugs on the horizon for idiopathic pulmonary fibrosis, a life-threatening lung condition – 6abc Philadelphia

November 13, 2024

Rejuvenating lung stem cells for idiopathic pulmonary fibrosis – drugdiscoverynews.com